The European Journal of Health Economics

, Volume 12, Issue 1, pp 49–59 | Cite as

Generic substitution: micro evidence from register data in Norway

  • Dag Morten Dalen
  • Kari Furu
  • Marilena Locatelli
  • Steinar Strøm
Original Paper

Abstract

The importance of prices, doctor and patient characteristics, and market institutions for the likelihood of choosing generic drugs instead of the more expensive original brand-name version are examined. Using an extensive dataset extracted from The Norwegian Prescription Database containing all prescriptions dispensed to individuals in February 2004 and 2006 on 23 different drugs (chemical substances) in Norway, we find strong evidence for the importance of both doctor and patient characteristics for the choice probabilities. The price difference between brand and generic versions and insurance coverage both affect generic substitution. Moreover, controlling for the retail chain affiliation of the dispensing pharmacy, we find that pharmacies play an important role in promoting generic substitution. In markets with more recent entry of generic drugs, brand-name loyalty proves to be much stronger, giving less explanatory power to our demand model.

Keywords

Pharmaceutical industry Generic substitution Microdata Random utility model 

JEL Classifications

C 35 I 11 L 13 

References

  1. 1.
    Aronsson, T., Bergman, M., Rudholm, N.: The impact of generic drug competition on brand-name market shares—evidence from micro data. Rev. Ind. Organ. 19(4), 423–433 (2001)CrossRefGoogle Scholar
  2. 2.
    Berndt, E.R.: Pharmaceuticals in US Health Care: determinants of quantity and price. J. Econ. Perspect. 16, 45–66 (2002)Google Scholar
  3. 3.
    Brekke, K.R., Grasdal, A.L., Holmås, T.H.: Regulation and pricing of pharmaceuticals: reference pricing or price cap regulation? Eur. Econ. Rev. 53, 170–185 (2008)Google Scholar
  4. 4.
    Caves, R.E., Whinston, M.D., Hurwitz, M.A: Patent expiry, entry and competition in the US pharmaceutical industry. Brookings papers on economic activity. Microeconomics, pp. 1–48 (1991)Google Scholar
  5. 5.
    Coscelli, A.: The importance of doctors’ and patients’ preferences in the prescription decision. J. Ind. Econ. 3, 349–369 (2000)Google Scholar
  6. 6.
    Dalen, D.M., Strøm, S.: The pharmaceutical market in Norway. In: Sørgard, L. (ed.) Competition and welfare—the Norwegian experience, pp. 51–70. The Norwegian Competition Authority, Norway (2006)Google Scholar
  7. 7.
    Dalen, D.M., Strøm, S., Haabeth, T.: Price regulations and generic competition in the pharmaceutical market. Eur. J. Health Econ. 3, 208–214 (2006)Google Scholar
  8. 8.
    Frank, R.G., Salkever, D.S.: Generic entry and the pricing of pharmaceuticals. J. Econ. Manag. Strategy 6, 75–90 (1997)CrossRefGoogle Scholar
  9. 9.
    Furu, K.: Drug utilisation in a public health perspective: establishing a national prescription register in Norway. Norw. J. Epidemiol. 11(1), 55–60 (2001)Google Scholar
  10. 10.
    Furu, K.: Establishment of the nationwide Norwegian Prescription Database (NorPD)—new opportunities for research in pharmacoepidemiology in Norway. Norw. J. Epidemiol. 18(2), 129–136 (2008)Google Scholar
  11. 11.
    Grabowski, H., Vernon, J.: Brand loyalty; entry, and price competition in pharmaceuticals after the 1984 drug act. J. Law Econ. 35, 331–350 (1992)CrossRefGoogle Scholar
  12. 12.
    Hellerstein, J.: The importance of physician in the generic versus-trade name prescription decision. RAND J. Econ. 29, 109–136 (1998)CrossRefGoogle Scholar
  13. 13.
    Lundin, D.: Moral hazard in physician prescription behaviour. J. Health Econ. 19(5), 639–662 (2000)CrossRefGoogle Scholar
  14. 14.
    Norwegian Association of Pharmaceutical Manufacturers: Facts and figures. Norwegian Association of Pharmaceutical Manufacturers, Oslo, Norway (2008)Google Scholar
  15. 15.
    Pavcnik, N.: Do pharmaceutical prices respond to potential patient out-of-pocket expenses? RAND J. Econ. 33(3), 469–487 (2002)CrossRefGoogle Scholar
  16. 16.
    Regan, T.L.: Generic entry, price competition, and market segmentation in the prescription drug market. Int. J. Ind. Org. 26(4), 930–948 (2008)CrossRefGoogle Scholar
  17. 17.
    Scherer, F.M.: Pricing, profits, and technological progress in the pharmaceutical industry. J. Econ. Perspect. 7, 97–115 (1993)Google Scholar
  18. 18.
    Scott Morton, F.M.: Barriers to entry, brand advertising, and generic entry in the US pharmaceutical industry. Int. J. Ind. Org. 18, 1085–1104 (2000)CrossRefGoogle Scholar
  19. 19.
    Train, K.: Discrete choice methods with simulation. Cambridge University Press, Cambridge (2003)CrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  • Dag Morten Dalen
    • 1
  • Kari Furu
    • 2
  • Marilena Locatelli
    • 3
  • Steinar Strøm
    • 3
  1. 1.BI Norwegian School of ManagementOsloNorway
  2. 2.The Norwegian Institute of Public HealthOsloNorway
  3. 3.University of Turin and the Frisch CentreOsloNorway

Personalised recommendations